RAF1 and hepatocellular carcinoma: Sorafenib was chosen as a positive control, which is a multi-kinase inhibitor that targets c-Raf, B-Raf and VEGF receptor, and approved as systemic treatment for advanced hepatocellular carcinoma (Wei et al., 2015; Coriat et al., 2012).